The role of cerebrospinal fluid biomarkers in the differential diagnosis of idiopathic normal pressure hydrocephalus

Abstract

Idiopathic normal pressure hydrocephalus is a chronic neurodegenerative diseases, characterized by remodelling of cerebrospinal fluid spaces and manifested by a tride of symptoms: gait disturbances, dementia and impaired urination. For the differencial diagnosis of idiopathic normal pressure hydrocephalus magnetic resonance imaging and invasive tests (tap-test, infusion test, external lumbar drain) are useful. The modern diagnostic option for idiopathic normal pressure hydrocephalus is assessment of cerebrospinal fluid biomarkers. It allows with high accuracy differentiate idiopathic normal pressure hydrocephalus with a number of neurodegenerative diseases and to recrut patients for surgery on time with maximal benifit. Present manuscript summarize results of researches of cerebrospinal fluid biomarkers utility in diagnosis of idiopathic normal pressure hydrocephalus. Detail analizis of role of each biomarker was done. The most important for differential diagnosis of idiopathic normal pressure hydrocephalus are following: β-amyloid (42, 40, 38) soluble amyloid precursor proteins (α, β), common and phosphorylated tau-protein.

Keywords

normal pressure hydrocephalus / Alzheimer disease / neurodegeneration / dementia / biomarkers / beta-amyloid / tau-protein

References

[1] Agren-Wilsson, A. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus / А. Agren-Wilsson [et al.] // Acta Neurold Scand. – 2007. – Vol. 117, № 6. – P. 333–339.

[2] Bech, R.A. Shunting effects in patients with idiopathic normal pressure hydrocephalus; correlation with cerebral and leptomeningeal biopsy findings / R.A. Bech, G. Waldemar, F. Gjerris // ActaNeurochir (Wien). – 1999. – Vol. 141, № 6. – P. 633–0639.

[3] Blennow, K. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease / K. Blennow [et al.] // Nat Rev Neurol. – 2010. – Vol. 6, № 3. – P. 131–144.

[4] Cabral, D. Frequency of Alzheimer’s disease pathology at autopsy in patients with clinical normal pressure hydrocephalus / D. Cabral [et al.] // Alzheimers Dement. – 2011. – Vol. 7, № 5. – P. 509–513.

[5] Cole, S.L. The Alzheimer’s disease beta-secretase enzyme, BACE1 / S.L. Cole, R. Vassar // MolNeurodegener. – 2007. – Vol. 15. – P. 2–22.

[6] Ghosh, S. Diagnosis and prognosis in idiopathic normal pressure hydrocephalus / S. Ghosh, C. Lippa // Am J Alzheimers Dis Other Demen. – 2014. – Vol. 29, № 7. – P. 583–589.

[7] Glenner, G.G. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein / G.G. Glenner, C.W. Wong // Biochem Biophys Res Commun. – 1984. – Vol. 120, № 3. – P. 885–890.

[8] Hamlat, A. Idiopathic normal pressure hydrocephalus: theoretical concept of a spinal etiology / A. Hamlat [et al.] // Med Hypotheses. – 2006. – Vol. 67, № 1. – P. 110–114.

[9] Hanger, D.P. Mediators of tau phosphorylation in the pathogenesis of Alzheimer’s disease / D.P. Hanger, A. Seereeram, W. Noble // Expert Rev Neurother. – 2009. – Vol. 11, № 9. – P. 1647–1666.

[10] Hiraoka, K. Prevalence of idiopathic normal-pressure hydrocephalus in the elderly population of a Japanese rural community / K. Hiraoka, K. Meguro, E. Mori // Neurol Med Chir (Tokyo). – 2008. – Vol. 48, № 5. – P. 197–199.

[11] Jaraj, D. Prevalence of idiopathic normal-pressure hydrocephalus / D. Jaraj [et al.] // Neurology. – 2014. – Vol. 82, № 16. – P. 1449–1454.

[12] Jingami, N. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer’s disease / N. Jingami, M. Asada-Utsugi, K. Uemura [et al.] // J Alzheimers Dis. – 2015. – Vol. 45, № 1. – P. 109–115.

[13] Karran, E. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics / E. Karran, M. Mercken, B. De Strooper // Nat Rev Drug Discov. – 2011. – Vol. 10, № 9. – P. 698–712.

[14] Li, X. Analysis of potential diagnostic biomarkers in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics / X. Li [et al.] // ActaNeurochir (Wien). – 2006. – Vol. 148, № 8. – P. 859–864.

[15] Lins, H. Immunoreactivities of amyloid beta peptide ((1-42)) and total tau protein in lubar cerebrospinal fluid of patient with normal pressure hydrocephalus // H. Lins [et al.] // J Neural Transm (Vienna). – 2004. – Vol. 111, № 3. – P. 2732–2780.

[16] Luikku, A. J. Multimodal analysis to predict shunt surgery outcome of 284 patients with suspected idiopathic normal pressure hydrocephalus. A. J. Luikku [et al.] // ActaNeurochir (Wien). – 2016. – Vol. 158, № 12. – P. 2311–2319.

[17] Mattsson, N. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment / N. Mattsson [et al.] // JAMA. – 2009. – Vol. 302. – P. 385–393.

[18] Nakajima, N. Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus / M. Nakajima [et al.] // ActaNeurochir (Wien). – 2011. – Vol. 153, № 6. – P. 1339–1346.

[19] Picascia, M. A review of cognitive impairment and differential diagnosis in idiopathic normal pressure hydrocephalus / M. Picascia, [et al.] // Funct Neurol. – 2015. – Vol. 30, № 4. – P. 217–228.

[20] Pyykkö, O.T. Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus / O.T. Pyykkö [et al.] // PLoS One. – 2014. – Vol. 9, № 3. – P. 919–974.

[21] Roe, C.M. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later / C.M. Roe [et al.] // Neurology. – 2013. – Vol. 80, № 19. – P. 1784–1791.

[22] Schirinzi T. A clinical and biochemical analysis in the differential diagnosis of idiopathic normal pressure hydrocephalus / T. Schirinzi [et al.] // Front Neurol. – 2015. – Vol. 86, № 6. – P. 6–86.

[23] Tullberg, M. Cerebrospinal fluid markers before and after shunting in patients with secondary and idiopathic normal pressure hydrocephalus / M. Tullberg [et al.] // Cerebrospinal Fluid Res. – 2008. – P. 5–9.

[24] Visser, P. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study / P. Visser [et al.] // Lancet Neurol. – 2009. – Vol. 8. – P. 619–627.

RIGHTS & PERMISSIONS

Gavrilov G.V., Adleyba B.G., Stanishevskiy A.V., Gaydar B.V., Svistov D.V., Lobzin V.Yu., Kolmakova K.A.